Q2 Earnings Forecast for OPKO Health Issued By HC Wainwright

OPKO Health, Inc. (NASDAQ:OPK) – HC Wainwright lifted their Q2 2025 earnings per share (EPS) estimates for shares of OPKO Health in a research note issued to investors on Wednesday, March 12th. HC Wainwright analyst Y. Chen now forecasts that the biotechnology company will post earnings per share of ($0.07) for the quarter, up from their previous forecast of ($0.08). HC Wainwright currently has a “Buy” rating and a $3.00 target price on the stock. The consensus estimate for OPKO Health’s current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for OPKO Health’s FY2025 earnings at ($0.30) EPS.

OPKO Health (NASDAQ:OPK) last released its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.09. The business had revenue of $183.60 million during the quarter, compared to analyst estimates of $155.42 million. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%.

OPK has been the subject of several other research reports. StockNews.com upgraded shares of OPKO Health from a “sell” rating to a “hold” rating in a research report on Monday, March 3rd. Barrington Research restated an “outperform” rating and issued a $2.25 target price on shares of OPKO Health in a report on Wednesday, March 12th.

OPKO Health Price Performance

OPK stock opened at $1.74 on Monday. The firm has a 50-day moving average of $1.62 and a two-hundred day moving average of $1.57. The firm has a market capitalization of $1.17 billion, a PE ratio of -9.16 and a beta of 1.70. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. OPKO Health has a one year low of $0.86 and a one year high of $2.04.

Institutional Trading of OPKO Health

A number of institutional investors and hedge funds have recently modified their holdings of OPK. Rubric Capital Management LP boosted its holdings in OPKO Health by 9.6% in the 3rd quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock valued at $72,573,000 after purchasing an additional 4,284,336 shares during the period. Millennium Management LLC boosted its stake in OPKO Health by 85.3% in the 4th quarter. Millennium Management LLC now owns 4,588,526 shares of the biotechnology company’s stock valued at $6,745,000 after buying an additional 2,112,382 shares in the last quarter. Lazard Asset Management LLC boosted its stake in shares of OPKO Health by 143.6% in the 4th quarter. Lazard Asset Management LLC now owns 2,548,667 shares of the biotechnology company’s stock valued at $3,746,000 after purchasing an additional 1,502,342 shares in the last quarter. Altshuler Shaham Ltd acquired a new stake in shares of OPKO Health during the 4th quarter worth about $2,082,000. Finally, Norges Bank bought a new position in shares of OPKO Health in the fourth quarter valued at approximately $1,657,000. 64.63% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost bought 500,000 shares of OPKO Health stock in a transaction on Wednesday, January 15th. The stock was purchased at an average cost of $1.48 per share, for a total transaction of $740,000.00. Following the completion of the purchase, the chief executive officer now directly owns 213,036,477 shares of the company’s stock, valued at $315,293,985.96. The trade was a 0.24 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders purchased 764,971 shares of company stock valued at $1,145,692 in the last quarter. Company insiders own 47.26% of the company’s stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.